CathWorks Ltd.

Medical device company Applied Medical has been awarded $381,705,005 in damages after a federal jury in California found Medtronic liable for violations of federal and state antitrust laws. In February 2023, Applied Medical filed a federal antitrust lawsuit in the U.S. District Court for the Central District of California against Medtronic, claiming the company engaged in anticompetitive conduct by stifling competition for advanced bipolar surgical devices, which are tools used by surgeons to cut tissue and seal blood vessels during surgeries. Applied alleged that Medtronic, which develops, manufactures and sells medical therapy devices, entered into bundling and exclusive-deal arrangements with hospitals and other purchasing groups, providing discounts or rebates for its surgical products only if the organization also purchased Medtronic's LigaSure bipolar devices. According to the complaint, Applied claimed that the deals made it economically difficult for hospitals to purchase its advanced bipolar device, the Voyant Intelligent Energy System. On Feb. 5, following a 10-day jury trial, jurors sided with Applied Medical, stating that Medtronic was found to have unlawfully monopolized the bipolar device market. Applied was awarded nearly $382 million in damages. According to news reports , Medtronic said it was disappointed with the jury's verdict and plans to appeal. THE LARGER TREND In July 2023, the Federal Trade Commission (FTC) filed an Amicus brief detailing the legal framework that should apply in exclusive-dealing and bundling antitrust claims, and, although the FTC did not take a position on the merits of the Applied v. Medtronic case, it stated that Medtronic's arguments about how to evaluate the antitrust law were legally incorrect. The FTC also said that if the arguments were adopted, they could undermine the enforcement of competition laws in healthcare markets and other sectors, and have real effects on competition and patient choice. Earlier this week, ahead of the verdict, Medtronic also announced plans to acquire medical device company CathWorks in a deal valued at up to $585 million, with additional undisclosed earn-out payments. "Medtronic is thrilled to move forward with our option to officially acquire CathWorks. Through our co-promotion agreement, we've seen how CathWorks can disrupt the traditional wire-based FFR segment and leverage the power of data and AI to deliver innovative solutions that assist physicians at every step of a patient's journey, from diagnosis to treatment," Jason Weidman, senior vice president and president of the coronary and renal denervation business, which is part of the cardiovascular portfolio at Medtronic, said in a statement. "This acquisition allows Medtronic to transform the cath lab with a technology that provides real-time data, informs individualized treatment approaches, and drives new standards of care." Medtronic is a publicly traded company with a reported market cap of $131.66 billion. Its stock is currently trading on the New York Stock Exchange [NYSE: MDT] at around $102.69 per share.

(医药健闻 2026年2月5日讯) 企业动态 医械巨头贝朗美国宣布一项重要的领导层过渡计划。现任首席执行官Rob Albert将在为公司服务长达42年后荣退。自2026年5月1日起，现任贝朗英国公司总经理Michael Parden将接任贝朗美国首席执行官一职。 美敦力宣布，将行使选择权，以最高5.85亿美元（约40亿人民币）收购以色列心血管AI影像公司CathWorks，进一步强化心血管产品组合。此次收购交易正等待美国联邦贸易委员会（FTC）批准，美敦力预计在2026财年末（4月底）获批。CathWorks是一家总部位于以色列卡法尔萨巴的医疗技术公司，成立于2013年。该公司专注于开发基于计算机视觉和人工智能技术的心血管影像和治疗解决方案，致力于为经皮冠状动脉介入治疗（PCI）决策提供客观数据，并将冠状动脉血管造影从视觉评估提升为基于FFR（分数流量储备）的决策工具。 西门子医疗公司宣布，其位于爱尔兰索兹（Swords）的免疫分析仪器研发卓越中心正式启用。截至目前，西门子医疗已为该设施投资超1200万美元，且计划进一步追加投资，以推动研发进程并强化可持续发展举措。2023年1月，西门子医疗宣布在索兹成立免疫分析仪器研发卓越中心，专注于传染病、癌症和血液疾病检测仪器的创新。 雅培在在墨西哥克雷塔罗州（Querétaro）正式启用全新电生理制造基地。该基地总投资2亿美元，将聚焦于心律失常疾病诊疗设备的研发、生产。 诺华(Novartis)公布2025年第四季度和全年业绩。第四季度净销售额133.36亿美元，上年同期为131.53亿美元。季度营业利润36.16亿美元，上年同期为35.3亿美元。季度净利润24.04亿美元，上年同期为28.2亿美元。全年净销售额545.32亿美元，上年为503.17亿美元。全年营业利润176.44亿美元，上年为145.44亿美元。全年净利润139.67亿美元，上年为119.39亿美元。 葛兰素史克(GSK)公布2025年第四季度和全年业绩。第四季度营业额86.18亿英镑，上年同期为81.17亿英镑。季度营业利润11亿英镑，上年同期为6.96亿英镑。归属股东的净利润6.36亿英镑，上年同期为4.14亿英镑。全年营业额326.67亿英镑，上年为313.76亿英镑。全年营业利润79.32亿英镑，上年为40.21亿英镑。全年归属股东的净利润57.16亿英镑，上年为25.75亿英镑。 礼来(Eli Lilly)公布2025年第四季度和全年业绩。第四季度营收192.92亿美元，上年同期为135.33亿美元，同比增长43%。季度营业利润83.73亿美元，上年同期为51.49亿美元，同比增长63%。季度净利润66.36亿美元，上年同期为44.1亿美元，同比增长50%。全年营收651.79亿美元，上年为450.43亿美元，同比增长45%。全年营业利润263.02亿美元，上年为128.99亿美元，同比增长104%。全年净利润206.4亿美元，上年为105.9亿美元，同比增长95%。 安进(Amgen)公布2025年第四季度和全年业绩。第四季度总营收98.66亿美元，上年同期为90.86亿美元。季度营业利润27.2亿美元，上年同期为23.11亿美元。季度净利润13.33亿美元，上年同期为6.27亿美元。全年总营收367.51亿美元，上年为334.24亿美元。全年营业利润90.8亿美元，上年为72.58亿美元。全年净利润77.11亿美元，上年为40.9亿美元。 GE医疗(GE HealthCare)公布2025年第四季度和全年业绩。第四季度总营收56.98亿美元，上年同期为53.19亿美元。季度营业利润8.27亿美元，上年同期为8.01亿美元。季度归属公司的净利润5.89美元，上年同期为7.2亿美元。全年总营收206.25亿美元，上年为196.72亿美元。全年营业利润27.63亿美元，上年为26.25亿美元。全年归属公司净利润20.84亿美元，上年为19.93亿美元。 波士顿科学(Boston Scientific)公布2025年第四季度和全年业绩。第四季度净销售额52.86亿美元，上年同期为45.61亿美元。季度营业利润8.25亿美元，上年同期为6.75亿美元。季度归属公司普通股东的净利润6.72美元，上年同期为5.66亿美元。全年净销售额200.74亿美元，上年为167.47亿美元。全年营业利润36.13亿美元，上年为26.03亿美元。全年归属公司普通股东的净利润28.98亿美元，上年为18.53亿美元。 艾默生(Emerson)公布截至2025年12月31日的第一财季业绩。季度净销售额43.46亿美元，上年同期为41.75亿美元，同比增长4%。季度普通股东净利润6.05亿美元，上年同期为5.85亿美元。 诺和诺德(Novo Nordisk)公布2025年全年业绩。全年净销售额3090.64亿丹麦克朗，上年为2904.03亿丹麦克朗，同比增长6%。全年营业利润(EBIT)1276.58亿丹麦克朗，上年为1283.39亿丹麦克朗，同比下降1%。全年净利润1024.34亿丹麦克朗，上年为1009.88亿丹麦克朗，同比增长1%。 辉瑞(Pfizer)公布2025年第四季度和全年业绩。第四季度营收175.57亿美元，上年同期177.63亿美元，同比下降1%。季度净亏损16.48亿美元，上年同期净利润4.1亿美元。全年营收625.79亿美元，上年为636.27亿美元，同比下降2%。全年净利润77.71亿美元，上年为80.31亿美元，同比下降3%。 默沙东(Merck & Co., Inc.)公布2025年第四季度和全年业绩。第四季度销售额164亿美元，上年同期156.24亿美元，同比增5%。其中，制药业务销售额148.43亿美元，动物保健业务销售额15.05亿美元。季度净利润29.63亿美元，上年同期37.43亿美元，同比下降21%。全年销售额650.11亿美元，上年为641.68亿美元，同比增长1%。全年净利润182.54亿美元，上年为171.17亿美元，同比增长7%。其中，制药业务销售额581.42亿美元，动物保健业务销售额63.54亿美元。 赛多利斯2025年初步业绩公布，年度销售收入较2024年显著增长，增幅按固定汇率计算为7.6%，达到35.38亿欧元。按报告增长率为4.7%，主要受美元走弱影响。基本EBITDA以11.2%的超比例增速攀升至10.52亿欧元。基本净利润表现更为强劲，较2024年的2.8亿欧元增长18.2%，达到3.31亿欧元。 和铂医药发布截至2025年12月31日止正面盈利预告。根据对公司报告期内未经审计管理账目的初步审阅，预计2025年全年盈利将介于8800万美元至9500万美元之间，而截至2024年12月31日的年度盈利约为270万美元。经调整后盈利将介于9100万美元至9800万美元之间。 产业动态 圣因生物（SanegeneBio）与罗氏（Roche）旗下基因泰克（Genentech）达成一项全球研发合作与许可协议，双方将基于圣因生物专有的RNA干扰（RNAi）药物研发平台共同推进一款RNAi疗法的开发。根据协议，圣因生物将授权该药物的全球独家开发和商业化权利给基因泰克。圣因生物将获得2亿美元的首付款，并有权收取开发和销售里程碑付款，最高共计15亿美元。 云顶新耀宣布其间接全资附属公司与陕西麦科奥特医药科技股份有限公司达成战略协议，获得全球首创双靶点受体激动剂多肽MT1013在中国及亚太区（日本除外）的独家商业化授权，进一步巩固其在亚洲肾脏及自体免疫疾病领域的领导地位。云顶新耀需支付2亿元人民币首付款，以及最高达10.4亿元人民币的潜在监管及商业里程碑付款。 药明生物与Vertex Pharmaceuticals已针对一款创新三特异性T细胞衔接子（TCE）签署授权和研究服务协议。Vertex计划用于治疗B细胞介导的自身免疫性疾病。Vertex将获得该处于临床前阶段、计划用于治疗B细胞介导的自免疾病的三特异性TCE的全球独家开发及商业化权益。药明生物将获得一笔首付款，并有资格获得与开发、注册及销售相关的里程碑付款，以及产品上市后的销售提成。药明生物还将为其创新TCE提供一体化合同研究和开发服务。 阳光诺和与江苏威凯尔医药科技股份有限公司正式敲定深度战略合作，此次合作中，阳光诺和将根据协议约定比例获得1类创新药VC005外用凝胶（规格：1%）于中国大陆地区的未来商业化收益，与江苏威凯尔携手推进该药物III期临床试验及后续上市全流程。 诺和诺德的司美格鲁肽药片上市后的第二个完整星期，美国处方量超过了2.6万张。巴克莱分析师在一份报告中写道，在截至1月23日的一周内，司美格鲁肽药片的处方量为26109次，这表明该口服药的上市势头非常强劲。 诺华创新生物制剂可善挺（司库奇尤单抗）新适应症获得国家药品监督管理局批准，适用于治疗对非甾体类抗炎药（NSAID）应答不佳的活动性放射学阴性中轴型脊柱关节炎成人患者（其客观征象表现为C反应蛋白（CRP）升高和/或磁共振成像（MRI）证据）。 丸红制药旗下创新抗菌药物醋酸来法莫林注射用浓溶液（中文商标：信乐妥，英文商标：Xenleta）正式启动中国市场商业化进程，醋酸来法莫林片计划于今年4月上市。作为近20年来首个获批用于社区获得性肺炎（CAP）治疗的全新类别抗菌药物，信乐妥的成功上市标志着中国CAP治疗领域迎来重要突破，其2025年12月成功纳入国家医保目录。 拜耳宣布中国NMPA已批准达罗他胺的新适应症上市，联合雄激素剥夺疗法（ADT）用于治疗转移性激素敏感性前列腺癌（mHSPC）患者。这是该药在中国获批的第3项适应症。 国药集团中国生物武汉生物制品研究所研发的三价流感病毒裂解疫苗正式获得国家药品监督管理局（NMPA）核准签发的《药品注册证书》。中国生物流感疫苗再添新成员，与现有四价流感疫苗共同构成抵御流感威胁的协同化产品矩阵。 溪砾科技（ReviR）宣布，其与晶泰科技深度合作的创新药管线RTX-117获得国家药品监督管理局（NMPA）又一罕见病适应症的临床审批，将开展用于治疗白质消融性白质脑病（Vanishing White Matter, VWM）的临床试验。 英矽智能于2025年1月对外授权给美纳里尼集团的MEN2501项目已在I期临床试验中完成首例患者给药，根据双方合作协议，英矽智能已获得由美纳里尼支付的3900万港币里程碑付款。MEN2501（ISM9682）是一款具备高度差异化的小分子抑制剂，靶向驱动蛋白KIF18A，临床前数据显示对染色体不稳定性癌症具有显著的抑制活性。作为一项旨在加速变革性抗肿瘤疗法开发的战略合作，英矽智能以5.5亿美元合作总额将MEN2501项目对外授权给美纳里尼集团全资子公司Stemline Therapeutics。 卫材和渤健宣布，美国食品药品监督管理局（FDA）已受理卫材提交的关于仑卡奈单抗-irmb（美国商品名：LEQEMBI，中文商品名：乐意保）皮下自动注射器（SC-AI，商品名：LEQEMBI IQLIK）作为每周起始剂量用药的补充生物制品许可申请（sBLA），用于每周一次的起始剂量给药。仑卡奈单抗适用于治疗处于轻度认知障碍（MCI）或轻度痴呆阶段（统称为早期阿尔茨海默病）的阿尔茨海默病（AD）患者。

Medtronic will shell out $585 million to buy privately held partner CathWorks that focuses on coronary artery disease and its treatment.\n Just weeks after announcing it would \"step up\" its acquisitions this year, Medtronic said it will shell out up to $585 million to buy privately held partner CathWorks, which focuses on coronary artery disease and its treatment.At the J.P. Morgan Healthcare Conference in early January, Medtronic Chief Financial Officer Thierry Piéton said that after boosting day-to-day operations, the medtech giant was in a position to boost M&A this year, and it was “going to step up in that area.”Less than a month later, and that is ringing true with a new deal to buy out Israel-based CathWorks. The acquisition is valued at up to $585 million, \"with potential undisclosed earn-out payments post-acquisition\" also in the mix, according to a Tuesday, Feb. 3, statement. The buyout spawned from an original 2022 partnership that included co-promotion of its FFRangio system in the U.S., Europe and Japan, where it is commercially available, the company said in a press release.The FFRangio platform gives a comprehensive physiological assessment of a patient’s entire coronary tree using routine coronary angiograms (X-rays). The company said clinical evidence demonstrates excellent diagnostic accuracy and promising clinical outcomes when compared with wire-based FFR. “Through our co-promotion agreement, we\'ve seen how CathWorks can disrupt the traditional wire-based FFR segment and leverage the power of data and AI to deliver innovative solutions that assist physicians at every step of a patient\'s journey, from diagnosis to treatment,\" Jason Weidman, a Medtronic senior vice president and president of its coronary and renal denervation business, said in a statement. “This acquisition allows Medtronic to transform the cath lab with a technology that provides real-time data, informs individualized treatment approaches, and drives new standards of care.”The platform is touted as the only angiography-derived system that delivers FFR values for the entire coronary tree. Additionally, it provides intraprocedural optimization tools, including assessment of the physiological impact of lesion treatment and interactive sizing tools to measure lesion dimensions.The acquisition is expected to be completed by the end of April, pending clearance from the Federal Trade Commission. CathWorks will then be folded into the Medtronic structure.